Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma

Marco Colleoni, Francesco Sartori, Francesco Calabrò, Patrizia Nelli, Giovanni Vicario, Gigliola Sgarbossa, Fernando Gaion, Luigi Bortolotti, Lamberto Toniolo, Paolo Manente

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Aims and background: Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods: We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,000 mg/m2) tor 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m2) and mitomycin-C (10 mg/m2) day 1 every 4 weeks for 4 cycles. Results: Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects after intracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions: The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.

Original languageEnglish
Pages (from-to)53-56
Number of pages4
JournalTumori
Volume82
Issue number1
Publication statusPublished - Jan 1996

Fingerprint

Drug Therapy
Survival
Epirubicin
Cytarabine
Alopecia
Residual Neoplasm
Mitomycin
Cisplatin
Disease Progression
Anemia
Appointments and Schedules
Malignant Mesothelioma
Kidney
Pain
Therapeutics

Keywords

  • intracavitary chemotherapy
  • mesothelioma
  • surgery
  • systemic chemotherapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Colleoni, M., Sartori, F., Calabrò, F., Nelli, P., Vicario, G., Sgarbossa, G., ... Manente, P. (1996). Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori, 82(1), 53-56.

Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. / Colleoni, Marco; Sartori, Francesco; Calabrò, Francesco; Nelli, Patrizia; Vicario, Giovanni; Sgarbossa, Gigliola; Gaion, Fernando; Bortolotti, Luigi; Toniolo, Lamberto; Manente, Paolo.

In: Tumori, Vol. 82, No. 1, 01.1996, p. 53-56.

Research output: Contribution to journalArticle

Colleoni, M, Sartori, F, Calabrò, F, Nelli, P, Vicario, G, Sgarbossa, G, Gaion, F, Bortolotti, L, Toniolo, L & Manente, P 1996, 'Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma', Tumori, vol. 82, no. 1, pp. 53-56.
Colleoni M, Sartori F, Calabrò F, Nelli P, Vicario G, Sgarbossa G et al. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori. 1996 Jan;82(1):53-56.
Colleoni, Marco ; Sartori, Francesco ; Calabrò, Francesco ; Nelli, Patrizia ; Vicario, Giovanni ; Sgarbossa, Gigliola ; Gaion, Fernando ; Bortolotti, Luigi ; Toniolo, Lamberto ; Manente, Paolo. / Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. In: Tumori. 1996 ; Vol. 82, No. 1. pp. 53-56.
@article{2251ba3e684245cdb530ee7c1891bb74,
title = "Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma",
abstract = "Aims and background: Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods: We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,000 mg/m2) tor 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m2) and mitomycin-C (10 mg/m2) day 1 every 4 weeks for 4 cycles. Results: Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects after intracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions: The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.",
keywords = "intracavitary chemotherapy, mesothelioma, surgery, systemic chemotherapy",
author = "Marco Colleoni and Francesco Sartori and Francesco Calabr{\`o} and Patrizia Nelli and Giovanni Vicario and Gigliola Sgarbossa and Fernando Gaion and Luigi Bortolotti and Lamberto Toniolo and Paolo Manente",
year = "1996",
month = "1",
language = "English",
volume = "82",
pages = "53--56",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma

AU - Colleoni, Marco

AU - Sartori, Francesco

AU - Calabrò, Francesco

AU - Nelli, Patrizia

AU - Vicario, Giovanni

AU - Sgarbossa, Gigliola

AU - Gaion, Fernando

AU - Bortolotti, Luigi

AU - Toniolo, Lamberto

AU - Manente, Paolo

PY - 1996/1

Y1 - 1996/1

N2 - Aims and background: Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods: We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,000 mg/m2) tor 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m2) and mitomycin-C (10 mg/m2) day 1 every 4 weeks for 4 cycles. Results: Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects after intracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions: The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.

AB - Aims and background: Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods: We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,000 mg/m2) tor 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m2) and mitomycin-C (10 mg/m2) day 1 every 4 weeks for 4 cycles. Results: Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects after intracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions: The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.

KW - intracavitary chemotherapy

KW - mesothelioma

KW - surgery

KW - systemic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=15844374950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15844374950&partnerID=8YFLogxK

M3 - Article

C2 - 8623505

AN - SCOPUS:15844374950

VL - 82

SP - 53

EP - 56

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -